Bionex Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-12-2024
- Paid Up Capital ₹ 1.00 M
as on 25-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.65 M
as on 25-12-2024
- Revenue 50.05%
(FY 2020)
- Profit 11.49%
(FY 2020)
- Ebitda 108.99%
(FY 2020)
- Net Worth 19.91%
(FY 2020)
- Total Assets 120.42%
(FY 2020)
About Bionex Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.65 M.
Mahesh Shelke, Rahul Dhamane, Anil Tanpure, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239PN2011PTC139477
- Company No.
139477
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 May 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bionex Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Shelke  | Director | 06-Nov-2012 | Current |
| Rahul Dhamane | Director | 06-Nov-2012 | Current |
| Anil Tanpure | Director | 06-Nov-2012 | Current |
| Vinay Garud | Director | 06-Nov-2012 | Current |
| Manoj Gajare | Director | 06-Nov-2012 | Current |
Financial Performance of Bionex Lifesciences.
Bionex Lifesciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 50.05% increase. The company also saw a substantial improvement in profitability, with a 11.49% increase in profit. The company's net worth Soared by an impressive increase of 19.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bionex Lifesciences?
In 2019, Bionex Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Jun 2020 | ₹0.67 M | Open |
Others Creation Date: 28 Nov 2019 | ₹1.60 M | Open |
Others Creation Date: 05 Jul 2016 | ₹2.39 M | Open |
How Many Employees Work at Bionex Lifesciences?
Bionex Lifesciences has a workforce of 15 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bionex Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bionex Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
